Akatinol Memantine, 20 mg, 28 pcs.

1 coated tablet contains:

Active substance:

memantine hydrochloride 10 mg;

Excipients:

lactose,

MCC

silica colloidal

talc,

magnesium stearate,

shell:

methacrylic acid copolymer,

sodium lauryl sulfate,

talc.

Pharmacodynamics

Being a non-competitive antagonist of N-methyl-D-aspartate (NMDA) receptors, it has a modulating effect on the glutamatergic system. Regulates ion transport, blocks calcium channels, normalizes membrane potential, improves the transmission of nerve impulses. Improves cognitive processes, increases daily activity.

Pharmacokinetics

After oral administration, Akatinol Memantine is rapidly and completely absorbed. The maximum plasma concentration is reached within 2-6 hours. With normal renal function, no cumulation of the drug was noted. Excretion proceeds in two phases. The elimination half-life is in the first phase - 4-9 hours, in the second phase - 40-65 hours.
It is excreted in urine.

Alzheimer's type dementia, vascular dementia, mixed dementia of all degrees of severity.

• individual hypersensitivity to the drug Akatinol Memantine;
• severe renal impairment;
• pregnancy;
• breast-feeding;
• children under 18 years old (due to insufficient data).

Carefully:

• thyrotoxicosis;
• epilepsy;
• convulsions (including history);
• myocardial infarction;
• heart failure.

Adverse reactions are classified by clinical manifestations (in accordance with the defeat of certain organ systems) and by the frequency of occurrence:

On the part of the body as a whole - general adverse reactions

Often headache

Rarely fatigue

Infections Rarely Fungal Infections

Mental Disorders Often Drowsiness

Rarely Confusion

Rarely Hallucinations

Frequency not set

Psychotic reactions

Disorders of the cardiovascular system

Rarely hypertension

Rarely Venous Thrombosis / Thromboembolism

Gastrointestinal Disorders Often Constipation

Rarely Nausea, Vomiting

Frequency not established Pancreatitis

Disorders from the central and peripheral nervous system

Often Dizzy

Rarely Gait Disorder

Very rare cramps

Hallucinations were observed mainly in patients with Alzheimer's disease at the stage of severe dementia.

There are separate reports of the occurrence of these adverse reactions when using the drug in clinical practice (data obtained after the drug was commercially available).

With simultaneous use with L-dopa drugs, dopamine agonists, anticholinergics, the effect of the latter may be enhanced.

With simultaneous use with barbiturates, antipsychotics, the effect of the latter may decrease.

When used together, it can change (strengthen or reduce) the effect of dantrolene or baclofen, so the doses of drugs should be selected individually. Concurrent administration with amantadine, ketamine, and dexamethorphan should be avoided.

Possible increase in plasma levels of cimetidine, procainamide, quinidine, kinin and nicotine while taking with memantine. It is possible to reduce the level of hydrochlorothiazide while taking it with memantine.

Inside, while eating. The dosage regimen is set individually. It is recommended to start treatment with the appointment of minimally effective doses.

Adults with dementia during the 1st week of therapy - at a dose of 5 mg / day, 2nd week - at a dose of 10 mg / day, 3rd week - at a dose of 15-20 mg / day. If necessary, a further weekly increase in dose of 10 mg is possible until a daily dose of 30 mg is reached.

The optimal dose is achieved gradually, with increasing doses every week.

Symptoms: increased severity of side effects.

Treatment: gastric lavage, intake of activated carbon, symptomatic therapy.

With caution prescribed for epilepsy, patients with thyrotoxicosis. The optimal dose is achieved gradually, with a weekly increase.

In patients with moderate to severe dementia, Alzheimer's disease usually impairs the ability to drive vehicles and control complex mechanisms.

In addition, memantine can cause a change in the rate of reaction, so patients receiving treatment on an outpatient basis should be especially careful when driving vehicles or operating machinery.

Coated tablets